For-Profit Dialysis Centers May Have Ignored Anemia Drug Warnings: Study

Even after the FDA warned that anemia drugs like Aranesp, Epogen and Procrit could increase the risk of death among patients, for-profit dialysis centers continued to use them more than non-profit centers, according to the findings of a new study.    

Researchers from the University of California, San Francisco, say for-profit dialysis centers continued to give patients large amounts of a class of anemia drug known as Erythropoiesis-stimulating agents (ESAs), even after a 2007 black box warning was added by the FDA warning that they should be using as little of the drugs as possible on their patients.

The study, published in the JAMA Internal Medicine medical journal on May 15, looked at the use of ESAs from February 1, 2007, before the warning was added, and compared the usage rates to those on February 1, 2008, after the warning.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Researchers found that both non-profit and for-profit dialysis centers showed reductions in use, but for-profit centers only dropped from 9,000 units per week to 8,300 units per week, while non-profit use of ESAs dropped from 5,600 units per week to 5,000 units weekly.

Experts say that it was not until 2011, when Medicare bundled all dialysis treatment costs together, so that there was no additional profit in using ESAs, that for-profit use dropped to levels comparable with non-profit use. However, there has been no study yet verifying that assumption.

Anemia Drug Health Risks

Aranesp (darbepoetin alfa), Epogen (Epoetin alfa) and Procrit (Epoetin alfa) are ESAs prescribed to patients with kidney disease, anemia, HIV and cancer to stimulate bones to increase the production of red blood cells. They are also prescribed to patients preparing to undergo major non-heart surgery to reduce the number of transfusions such patients must receive. Amgen manufactures all three drugs, though Procrit is sold and marketed by Johnson and Johnson.

In 2008, Aranesp sales were $3.1 billion, and Procrit accounted for $2.46 billion in sales. However, following studies that suggested the drugs carry serious, sometimes deadly side effects, sales have dropped in recent years.

The FDA issued a public health advisory regarding the drugs in 2007, saying that the Anemia drugs could increase the risk of injury or death at high doses. The FDA required the black box warning to alerting patients to the cardiovascular health risks. The black box warning is the strongest label warning the FDA can require of a medication.

The drugs are already restricted under an FDA-required risk evaluation and mitigation strategy (REMS). Doctors and hospitals that wish to prescribe the drugs will now have to undergo special training to identify high risk users and negative side effects.

A $762 million settlement was reached in December to resolve an Amgen whistleblower lawsuit, which alleged the drug maker illegally promoted the medication. The lawsuit claims Amgen encouraged doctors to use the drugs by overfilling vials by as much as 25 percent. It also alleges the drug company offered doctors discounts to use the drugs in large volume.

Other scandals surrounding the anemia drug involve Amgen offering false information regarding the safety of the drug. The company is reported to continue the use of lobbyists in congress to pressure lawmakers and the FDA to overlook claims of potential severe side effects, such as an increased risk of cancer and stroke.

1 Comments

  • PeggyJuly 1, 2016 at 5:58 am

    I believe it was 2006 my husband was given Procrit for anemia. After taking it for approximately one month, we found out by his doctor that he had an 18 inch blood clot from his groin down to his right knee. He had to immediately stop A treatment he was doing and get on blood thinners. To this day he is still on blood thinners. We have a recently found out that he has had several strokes that[Show More]I believe it was 2006 my husband was given Procrit for anemia. After taking it for approximately one month, we found out by his doctor that he had an 18 inch blood clot from his groin down to his right knee. He had to immediately stop A treatment he was doing and get on blood thinners. To this day he is still on blood thinners. We have a recently found out that he has had several strokes that he was unaware of. He is doing testing right now to find out how long ago these strokes started. He now has short-term memory problems and can get very angry quickly then NOT be angry just as quickly. Not sure if Procrit would have anything to do with it or not. I just seen a commercial on TV tonight about a different drug and it made me think of the Procrit so I looked it up. Now I question it!

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S.
Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S. (Posted 2 days ago)

A recently filed Depo-Provera lawsuit questions why Pfizer updated the drug label in Europe, to warn about the risk of meningioma brain tumors, but failed to provide the same Depo-Provera warnings to U.S. consumers and doctors.

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted 4 days ago)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.